- Home
- PUBM vs OCGN Comparison
PUBM vs OCGN Comparison
Compare PUBM & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PUBM
- OCGN
- Stock Information
- Founded
- PUBM 2006
- OCGN 2013
- Country
- PUBM United States
- OCGN United States
- Employees
- PUBM N/A
- OCGN N/A
- Industry
- PUBM Computer Software: Prepackaged Software
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PUBM Technology
- OCGN Health Care
- Exchange
- PUBM Nasdaq
- OCGN Nasdaq
- Market Cap
- PUBM 382.7M
- OCGN 321.7M
- IPO Year
- PUBM 2020
- OCGN N/A
- Fundamental
- Price
- PUBM $8.26
- OCGN $1.76
- Analyst Decision
- PUBM Buy
- OCGN Strong Buy
- Analyst Count
- PUBM 11
- OCGN 3
- Target Price
- PUBM $18.05
- OCGN $6.00
- AVG Volume (30 Days)
- PUBM 569.1K
- OCGN 7.7M
- Earning Date
- PUBM 11-11-2025
- OCGN 11-07-2025
- Dividend Yield
- PUBM N/A
- OCGN N/A
- EPS Growth
- PUBM N/A
- OCGN N/A
- EPS
- PUBM N/A
- OCGN N/A
- Revenue
- PUBM $292,208,000.00
- OCGN $4,754,000.00
- Revenue This Year
- PUBM N/A
- OCGN N/A
- Revenue Next Year
- PUBM $1.40
- OCGN N/A
- P/E Ratio
- PUBM N/A
- OCGN N/A
- Revenue Growth
- PUBM 3.53
- OCGN N/A
- 52 Week Low
- PUBM $7.01
- OCGN $0.52
- 52 Week High
- PUBM $17.74
- OCGN $1.90
- Technical
- Relative Strength Index (RSI)
- PUBM 44.09
- OCGN 69.06
- Support Level
- PUBM $8.19
- OCGN $1.31
- Resistance Level
- PUBM $8.58
- OCGN $1.90
- Average True Range (ATR)
- PUBM 0.30
- OCGN 0.15
- MACD
- PUBM 0.05
- OCGN 0.03
- Stochastic Oscillator
- PUBM 22.73
- OCGN 75.81
About PUBM PubMatic Inc.
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").